The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.

• Status: Completed
• Trial end date: 2006-01-01

Summary

Bipolar disorder is a psychiatric illness with clinical characteristics of mixed mania, grandiose delusions, and suicidality. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of patients with bipolar disorder type I or II.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Carbamazepine; Oxcarbazepine